Medicus Pharma to acquire Antev, advancing opportunity in prostate health solutions

Proactive - Interviews for investors

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a major strategic move: the company has entered into a binding letter of agreement to acquire Antev Ltd., a clinical-stage biotech company. Antev is developing Teverelix, a next-generation GnRH antagonist aimed at treating cardiovascular high-risk prostate cancer patients and patients with acute urinary retention (AUR) due to enlarged prostate. Bokhari highlighted that the acquisition will significantly strengthen Medicus Pharma’s drug development portfolio, positioning Teverelix as a first-in-class therapeutic to prevent AUR recurrence and address prostate cancer among patients with elevated cardiovascular risk—together representing a combined market opportunity of approximately $6 billion. Antev’s program includes an FDA-approved Phase 2b study, which is designed to randomize 390 men after successfully weaning off catheterization. This is highly relevant given that 85% of the nearly one million AUR episodes annually in the U.S. occur in men over the age of 60. Roughly 30% of these patients experience a recurrent episode within six months, creating a standalone $2 billion annual market for preventive treatment. Teverelix, therefore, offers a critical and differentiated solution in a space underserved by existing therapies, with the potential to redefine standards of care for aging male populations. The acquisition also aligns with Medicus Pharma’s mission to build a diversified pipeline targeting significant unmet medical needs with strong commercial potential. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch